Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin

NCT03161132 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Advanced Ovarian Cancer

Interventions

DRUG: Olaparib
DRUG: Pegylated Liposomal Doxorubicin

Sponsor

Grupo Español de Investigación en Cáncer de Ovario

Collaborators

[object Object]